Study to Evaluate Performance of the Organ Recovery Systems LifePort® Liver Transporter System, a Machine Perfusion System, for Liver Transplant (PILOT™)
A Prospective Randomized Multi-Center Study of the Use of the Organ Recovery Systems LifePort® Liver Transporter (LLT) System With Vasosol® as Compared to Static Cold Storage in Orthotopic Liver Transplants (Perfusion to Improve Liver Outcomes in Transplantation)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago Medical Center
-
Chicago, Illinois, United States, 60611
- Northwestern Memorial Hospital
-
-
New Jersey
-
Newark, New Jersey, United States, 07101
- Rutgers New Jersey Medical School
-
-
New York
-
Bronx, New York, United States, 10467
- Montefiore Medical Center
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
Rochester, New York, United States, 14642
- University of Rochester Strong Memorial Hospital
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- University of Cincinnati Medical Center
-
-
Utah
-
Murray, Utah, United States, 84107
- Intermountain Medical Center
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- University Of Virginia Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ≥18 years of age
- Active on the United Network for Organ Sharing (UNOS) waiting list for liver transplantation
- De novo liver transplant recipient
- Written informed consent required
Exclusion Criteria:
- Subject is a multi-organ transplant recipient
- Subject is antibodies blood group (ABO) liver incompatible
- Subject has severe systemic infection
- Subject is Human Immunodeficiency Virus (HIV) positive
- Subject has acute/fulminant liver failure
- Subject is pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Hypothermic Machine Perfusion
Hypothermic Machine Perfusion with Organ Recovery Systems LLT system
|
Organ Recovery Systems LifePort® Liver Transporter (LLT) System and Vasosol® Machine Perfusion Solution
|
|
Active Comparator: Static Cold Storage
Standard of Care - Static Cold Storage
|
Static cold storage (standard of care)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients in each arm with Early Allograft Dysfunction (EAD)
Time Frame: 7 days
|
EAD defined as total bilirubin ≥ 10 mg/dL or International Normalized Ratio (INR) ≥ 1.6 or Aspartate Aminotransferase (AST) >2000IU/L or Alanine Aminotransferase (ALT) > 2000 IU/L
|
7 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Stan Harris, Organ Recovery Systems
- Study Chair: Matthew Copithorne, Organ Recovery Systems
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 2017-US-01-ORS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Transplantation
-
NCT07275008Not yet recruitingLiver Transplantation | Auxiliary Liver Transplantation
-
NCT02118896CompletedLiver Transplantation | Kidney Transplantation | Heart Transplantation
-
NCT01614665CompletedLiver Transplantation | Kidney Transplantation | Heart Transplantation
-
NCT01371344TerminatedLiver Transplantation | Kidney Transplantation | Heart Transplantation
-
NCT01371331CompletedLiver Transplantation | Kidney Transplantation | Heart Transplantation
-
NCT01655563CompletedLiver Transplantation | Kidney Transplantation | Heart Transplantation
-
NCT04661254Not yet recruitingLiver Transplantation | Kidney Transplantation
-
NCT05153915CompletedLiver Transplantation | Kidney Transplantation
-
NCT05152628CompletedLiver Transplantation | Kidney Transplantation
-
NCT03910868CompletedLiver Transplantation | Kidney Transplantation
Clinical Trials on Hypothermic machine perfusion
-
NCT04644744RecruitingLiver Transplant Disorder | Hepatocellular Injury
-
NCT04744389RecruitingEnd Stage Liver DIsease
-
NCT07595627Not yet recruitingLiver Failure | Liver Transplant
-
NCT03031067CompletedLiver Diseases | Kidney Diseases
-
NCT03124641CompletedLiver Transplant | Hepatocellular Injury
-
NCT05574361Active, not recruiting
-
NCT05520320CompletedLiver Transplantation | Organ Preservation | Hypothermic Machine Perfusion
-
NCT05045794CompletedLiver Failure | End Stage Liver DIsease
-
NCT04812054RecruitingLiver Cirrhosis | Liver Tumor | Liver Transplant Failure and Rejection
-
NCT07585890RecruitingLiver Transplantation | Liver Cirrhosis | Acute Liver Failure | End-stage Liver Disease (ESLD)